Crunch Time For Idorsia Insomnia Therapy As Reviews Begin
Daridorexant Is Swiss Company's First Drug
Executive Summary
The US FDA has accepted the Swiss biotech's "huge" NDA file for daridorexant which the company hopes will be more successful on the insomnia market than other DORA sleep treatments such as Merck & Co's Belsomra.
You may also be interested in...
Idorsia Advances Lupus Drug Into Phase III Despite Mid-Stage Fail
The Swiss biotech is confident its S1P1 receptor modulator can be an effective treatment for lupus but the move into late-stage studies has raised some eyebrows.
An EpiPen For Heart Attacks? Idorsia Launches Phase III Study Of Selatogrel
Jean-Paul Clozel, whose firm Actelion was bought by Johnson & Johnson for $30bn, is back with his new company and a new approach to help save the lives of heart attack patients.
Finance Watch: Ten IPOs In One Week Bring 2021 Total To 80
Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering.